Everything you need to know about TMS for Parkinson's Disease: Addressing Motor Symptoms and Mood — how it works, what it costs, and how to find a provider who actually knows what they're doing.

Parkinson’s disease affects approximately 1 million Americans and 10 million people worldwide. While dopamine replacement therapies (levodopa, dopamine agonists) remain the cornerstone of treatment, many patients experience persistent symptoms despite optimal medication management. Transcranial magnetic stimulation offers a non-invasive approach that may complement pharmacotherapy by directly modulating the motor circuits that degenerate in Parkinson’s.

What You’ll Learn

• How Parkinson’s disrupts the balance between excitatory and inhibitory motor pathways
• Why the primary motor cortex and supplementary motor area are key TMS targets
• What research shows about TMS for motor symptoms, gait, and freezing of gait
• How TMS addresses Parkinson’s depression without worsening motor symptoms
• Practical considerations for patients with Parkinson’s seeking TMS

Understanding Parkinson’s Motor Circuitry

Parkinson’s disease involves the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, disrupting the basal ganglia circuits that coordinate movement. This dysfunction creates an imbalance between:

• Excitatory pathways from the motor cortex through the basal ganglia to thalamus and back to cortex
• Inhibitory pathways that normally suppress unwanted movements

The net effect is excessive cortical excitability and abnormal patterns of motor cortex activation. Patients experience:

• Bradykinesia (slowness of movement)
• Rigidity (stiffness and resistance to passive movement)
• Resting tremor (rhythmic shaking that subsides during voluntary movement)
• Postural instability (balance problems)

Beyond motor symptoms, many Parkinson’s patients also develop Parkinson’s disease depression, which affects up to 40% of patients and is often refractory to standard antidepressants.

How TMS Targets Motor Symptoms

Unlike TMS for depression, which targets the prefrontal cortex, Parkinson’s motor protocols focus on the primary motor cortex and, in some cases, the premotor cortex and supplementary motor area (SMA).

The primary motor cortex (M1) generates the electrical signals that travel down the corticospinal tract to muscles. In Parkinson’s, M1 shows abnormal patterns of synchronization and reduced responsiveness to dopaminergic input. By modulating M1 excitability, TMS may:

• Reduce pathologically elevated cortical excitability
• Restore more normal patterns of motor cortex activation
• Improve the brain’s responsiveness to remaining dopaminergic signaling

Low-frequency TMS (1 Hz) over the motor cortex has been most extensively studied for motor symptoms. This inhibitory protocol may reduce the excessive excitability that characterizes Parkinsonian motor cortex activity.

High-frequency TMS (5-25 Hz) over the SMA and premotor cortex has also shown benefits, particularly for gait and freezing of gait.

Evidence for Motor Symptom Improvement

A 2021 meta-analysis in Neurology reviewed 24 randomized controlled trials of TMS for Parkinson’s motor symptoms and found:

• Significant improvements in Unified Parkinson’s Disease Rating Scale (UPDRS) Part III motor scores with active versus sham TMS
• Effect sizes that were moderate for overall motor function
• Greatest benefits for bradykinesia and rigidity
• Variable effects on tremor, with some studies showing improvement and others showing no significant change
• Short-term benefits lasting hours to days after individual sessions, with cumulative effects from multiple sessions

Longer-term studies with maintenance protocols suggest that benefits can be sustained with periodic booster sessions.

TMS for Parkinson’s Depression

Depression in Parkinson’s presents unique challenges. It shares features with both primary mood disorders and secondary depression related to the neurobiological changes of Parkinson’s. Standard antidepressants may interact with dopaminergic medications or worsen motor symptoms.

TMS targeting the left dorsolateral prefrontal cortex (DLPFC) has shown efficacy for Parkinson’s depression in multiple studies. A 2020 randomized trial found that active TMS produced significantly greater improvement in depression scores (Hamilton Depression Rating Scale) compared to sham, with benefits emerging by the second week of treatment.

Importantly, TMS for Parkinson’s depression does not appear to worsen motor symptoms, a concern that has limited the use of some medications in this population.

Gait and Freezing of Gait

Freezing of gait (FOG), the sudden inability to initiate or continue walking despite intact leg function, is one of the most disabling and treatment-resistant features of Parkinson’s. FOG often leads to falls and loss of independence.

Repetitive TMS (rTMS) over the supplementary motor area (SMA) has shown particular promise for FOG. The SMA is critical for internally-generated motor sequences, and its function is particularly impaired in patients with freezing.

A 2022 study in Movement Disorders found that 10 sessions of high-frequency (10 Hz) SMA stimulation significantly reduced FOG episodes and improved gait velocity compared to sham treatment. Improvements were maintained at 4-week follow-up.

Combined Motor and Mood Treatment

An emerging approach involves simultaneous or sequential stimulation of both motor cortex and DLPFC targets, addressing motor symptoms and depression concurrently. This comprehensive approach may be particularly beneficial for patients with significant impairment in both domains.

Early studies of dual-target protocols have shown improvements in both UPDRS motor scores and depression ratings, suggesting that TMS can address the multidimensional impact of Parkinson’s disease.

Treatment Parameters

TMS for Parkinson’s typically involves:

1. Motor threshold determination using standard protocols
2. Motor cortex targeting with neuronavigation or EMG-guided localization
3. Low-frequency (1 Hz) stimulation over M1 for motor symptoms
4. High-frequency stimulation over SMA for gait dysfunction
5. DLPFC stimulation (if treating depression) at 10 Hz or theta burst
6. Multiple sessions (typically 10-20) over 2-4 weeks
7. Maintenance sessions as needed to sustain benefits

Who Is a Good Candidate?

Patients most likely to benefit from TMS for Parkinson’s include those with:

• Responsive motor symptoms that fluctuate with levodopa dosing
• Depression that has not responded to standard treatments
• Freezing of gait refractory to medication optimization
• Realistic expectations about modest, symptomatic rather than curative benefits
• Absence of significant cognitive impairment that might limit cooperation with treatment

The Current Landscape

While TMS for Parkinson’s is not FDA-cleared in the United States, it is increasingly offered at academic movement disorders centers. Patients should seek treatment from centers with experience in both TMS and Parkinson’s disease to ensure appropriate patient selection and protocol optimization.

As the evidence base grows, TMS may become a standard adjunctive treatment for selected Parkinson’s patients, offering meaningful improvements in quality of life when combined with optimal dopaminergic therapy.

If you have Parkinson’s disease and are experiencing persistent motor symptoms or depression despite optimal medication management, discuss TMS with your movement disorders neurologist to determine whether you may be a candidate.